244 related articles for article (PubMed ID: 22251968)
21. Clinical usefulness of the free web-based image analysis application ImmunoRatio for assessment of Ki-67 labelling index in breast cancer.
Yeo MK; Kim HE; Kim SH; Chae BJ; Song BJ; Lee A
J Clin Pathol; 2017 Aug; 70(8):715-719. PubMed ID: 28298390
[TBL] [Abstract][Full Text] [Related]
22. Digital quantification of KI-67 in breast cancer.
Del Rosario Taco Sanchez M; Soler-Monsó T; Petit A; Azcarate J; Lasheras A; Artal C; Gil M; Falo C; Pla MJ; Matias-Guiu X
Virchows Arch; 2019 Feb; 474(2):169-176. PubMed ID: 30465110
[TBL] [Abstract][Full Text] [Related]
23. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
24. Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma.
Arihiro K; Oda M; Ohara M; Kadoya T; Osaki A; Nishisaka T; Shiroma N; Kobayashi Y
Jpn J Clin Oncol; 2016 Dec; 46(12):1081-1087. PubMed ID: 27511992
[TBL] [Abstract][Full Text] [Related]
25. Correlation of manual semi-quantitative and automated quantitative Ki-67 proliferative index with OncotypeDXTM recurrence score in invasive breast carcinoma.
Finkelman BS; Meindl A; LaBoy C; Griffin BB; Narayan SP; Brancamp R; Siziopikou KP; Pincus JL; Blanco LZ
Breast Dis; 2022; 41(1):55-65. PubMed ID: 34397396
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas.
Aman NA; Doukoure B; Koffi KD; Koui BS; Traore ZC; Kouyate M; Toure I; Effi AB
Asian Pac J Cancer Prev; 2019 Jan; 20(1):73-79. PubMed ID: 30678383
[TBL] [Abstract][Full Text] [Related]
27. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
28. Automated characterization and counting of Ki-67 protein for breast cancer prognosis: A quantitative immunohistochemistry approach.
Mungle T; Tewary S; Arun I; Basak B; Agarwal S; Ahmed R; Chatterjee S; Maity AK; Chakraborty C
Comput Methods Programs Biomed; 2017 Feb; 139():149-161. PubMed ID: 28187885
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
[TBL] [Abstract][Full Text] [Related]
30. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells.
Hida AI; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Moriya T
Breast Cancer; 2015 Mar; 22(2):129-34. PubMed ID: 23543399
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis.
Mohammed ZM; Edwards J; Orange C; Mallon E; Doughty JC; McMillan DC; Going JJ
Histopathology; 2012 Aug; 61(2):283-92. PubMed ID: 22571413
[TBL] [Abstract][Full Text] [Related]
32. Automated assessment of Ki-67 in breast cancer: the utility of digital image analysis using virtual triple staining and whole slide imaging.
Hida AI; Omanovic D; Pedersen L; Oshiro Y; Ogura T; Nomura T; Kurebayashi J; Kanomata N; Moriya T
Histopathology; 2020 Sep; 77(3):471-480. PubMed ID: 32578891
[TBL] [Abstract][Full Text] [Related]
33. Automated quantitative analysis of Ki-67 staining and HE images recognition and registration based on whole tissue sections in breast carcinoma.
Feng M; Deng Y; Yang L; Jing Q; Zhang Z; Xu L; Wei X; Zhou Y; Wu D; Xiang F; Wang Y; Bao J; Bu H
Diagn Pathol; 2020 May; 15(1):65. PubMed ID: 32471471
[TBL] [Abstract][Full Text] [Related]
34. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
[TBL] [Abstract][Full Text] [Related]
35. Preoperative MRI Evaluation of Axillary Lymph Nodes in Invasive Ductal Carcinoma: Comparison of Luminal A Versus Luminal B Subtypes in a Paradigm Using Ki-67 and Receptor Status.
Plaza MJ; Handa P; Esserman LE
AJR Am J Roentgenol; 2017 Apr; 208(4):910-915. PubMed ID: 28140614
[TBL] [Abstract][Full Text] [Related]
36. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies.
Fasanella S; Leonardi E; Cantaloni C; Eccher C; Bazzanella I; Aldovini D; Bragantini E; Morelli L; Cuorvo LV; Ferro A; Gasperetti F; Berlanda G; Dalla Palma P; Barbareschi M
Diagn Pathol; 2011 Mar; 6 Suppl 1(Suppl 1):S7. PubMed ID: 21489202
[TBL] [Abstract][Full Text] [Related]
37. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
[TBL] [Abstract][Full Text] [Related]
38. The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of Its Optimal Cutoff Value.
Cho U; Kim HE; Oh WJ; Yeo MK; Song BJ; Lee A
Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):159-66. PubMed ID: 25789536
[TBL] [Abstract][Full Text] [Related]
39. Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas.
Ahmed ST; Ahmed AM; Musa DH; Sulayvani FK; Al-Khyatt M; Pity IS
Asian Pac J Cancer Prev; 2018 Apr; 19(4):955-959. PubMed ID: 29693354
[TBL] [Abstract][Full Text] [Related]
40. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study.
Varga Z; Cassoly E; Li Q; Oehlschlegel C; Tapia C; Lehr HA; Klingbiel D; Thürlimann B; Ruhstaller T
PLoS One; 2015; 10(4):e0123435. PubMed ID: 25885288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
